- Report
- January 2026
- 282 Pages
Global
From €5120EUR$5,850USD£4,437GBP
- Report
- September 2025
- 250 Pages
Global
From €3930EUR$4,490USD£3,406GBP
- Report
- March 2025
- 200 Pages
Global
From €3930EUR$4,490USD£3,406GBP
- Report
- June 2025
- 150 Pages
Global
From €3282EUR$3,750USD£2,844GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1313EUR$1,500USD£1,138GBP
- Report
- June 2025
- 400 Pages
Global
From €4331EUR$4,949USD£3,754GBP
- Report
- September 2025
- 150 Pages
Global
From €3895EUR$4,450USD£3,375GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,284USD£3,140GBP
- Report
- November 2023
- 135 Pages
Global
From €3501EUR$4,000USD£3,034GBP
- Report
- December 2024
- 30 Pages
Global
From €2407EUR$2,750USD£2,086GBP
- Report
- September 2024
- 343 Pages
Global
From €6958EUR$7,950USD£6,030GBP
- Report
- July 2024
- 150 Pages
Global
From €3282EUR$3,750USD£2,844GBP
- Report
- April 2023
- 117 Pages
Global
From €4157EUR$4,750USD£3,603GBP
- Report
- May 2024
- 137 Pages
Global
From €3500EUR$3,999USD£3,033GBP
- Report
- March 2023
- 147 Pages
Global
From €4331EUR$4,949USD£3,754GBP
- Report
- January 2023
- 85 Pages
Europe
From €1313EUR$1,500USD£1,138GBP
- Report
- January 2024
- 114 Pages
United States
€3063EUR$3,500USD£2,655GBP
- Report
- January 2024
- 156 Pages
United States
€3326EUR$3,800USD£2,882GBP
- Report
- May 2021
- 50 Pages
China
From €2276EUR$2,600USD£1,972GBP
- Report
- July 2018
- 33 Pages
Global
From €8752EUR$10,000USD£7,585GBP

Tiotropium is a long-acting anticholinergic drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both an inhaler and a dry powder inhaler. Tiotropium is the only long-acting anticholinergic approved for the treatment of COPD. It is also used to treat asthma and other respiratory conditions.
Tiotropium is a popular drug in the respiratory drugs market, as it is effective in treating COPD and other respiratory conditions. It is also well-tolerated, with few side effects. It is available in both generic and brand-name forms, making it accessible to a wide range of patients.
Some companies in the Tiotropium market include Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Show Less Read more